Introduction
Bacterial skin and soft tissue infections, including infected ulcers of the legs, are a serious problem in patients with diabetes mellitus. 1 Healing may be significantly delayed compared with in non-diabetic subjects, while osteomyelitis or consecutive sepsis constitute severe complications. 2 Appropriate antimicrobial therapy of such infections is a challenge, as there are two major obstacles. First, perfusion of the affected limbs is often impaired in diabetic patients due to micro-and macroangiopathy, which is believed to impede the delivery of antibiotics to the site of infection. Second, bacterial infections in patients with diabetes mellitus are often caused by multidrug-resistant pathogens, because they are frequently acquired in a nosocomial setting and patients have undergone repeated preceding antimicrobial therapies. 3 Ertapenem is a carbapenem with a broad antimicrobial spectrum covering extended-spectrum b-lactamase (ESBL)-producing strains and is approved for the treatment of foot infections of the skin and soft tissue in patients with diabetes mellitus. 4 For efficacy of antimicrobial treatment, it is important that the antibiotic achieves sufficient concentrations at the site of infection. However, there is a lack of data on the tissue pharmacokinetics of ertapenem, particularly in patients with diabetes mellitus. Soft tissue concentrations of ertapenem were reported after a single dose in healthy volunteers. 5 However, drug concentrations in the interstitial tissue fluid of healthy subjects may diverge from that in patients with diabetes, because occlusive arterial disease, systemic inflammation and other diabetes-induced pathophysiological alterations have been shown to significantly reduce the tissue penetration of several antibiotics. 6 -10 The present study set out to measure and compare the unbound, i.e. microbiologically active, concentrations of ertapenem after multiple doses in plasma as well as in the interstitial space fluid of inflamed and healthy subcutaneous tissues of diabetics with skin and soft tissue infections. The microdialysis technique was applied for continuous measurement of unbound drug concentrations in the interstitial space fluid of tissues.
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Methods
Protocol and patients
The protocol was performed at the University Hospital of Vienna in agreement with the principles of Good Clinical Practice, the Declaration of Helsinki in its current version and Austrian drug law. The protocol was approved by the Ethics Committee of the Medical University of Vienna (EK463-2007) and registered at www.clinicaltrials.gov (NCT00658866). All patients were informed in detail about the study and signed an informed consent form prior to enrolment. Major inclusion criteria were the diagnosis of diabetes mellitus and the current need for antibiotic therapy due to a skin or soft tissue infection and/or bacterially infected ulcer, located at the lower extremity. Patients had to be aged between 18 and 85 years. Other morbidities were inquired by consulting the patient and the patient's file. Creatinine clearance had to be .30 mL/ (min×1.73 m 2 of body surface area), according to the standard equation of Cockcroft and Gault.
Study drug
The study day was performed at steady-state. Therefore, prior to the study day, ertapenem (Invanz w ; 1 g of powder for preparation of infusion solution; Merck Sharp & Dohme, Hertfordshire, UK) was administered once daily over at least 3 days as intravenous infusions over 30 min.
Microdialysis and sampling periods
The principles of microdialysis have been described before in detail. 14 Microdialysis is based on the sampling of analytes from the extracellular space by means of a semi-permeable membrane at the tip of a microdialysis probe. Microdialysis measures unbound, i.e. antimicrobially active, drug concentrations. On the morning of study day 1, a microdialysis probe (cut-off 20 000 Da; CMA, Solna, Sweden) was inserted subcutaneously, proximal to the skin or soft tissue infection or the infected ulcer. Proximal to the first probe, a second microdialysis probe was inserted into healthy, non-inflamed subcutaneous tissue of the ipsilateral thigh. An equilibration period of 45 min was scheduled before the start of microdialysis measurements. During the study day, probes were continuously flushed with physiological saline solution at a flow rate of 1.5 mL/min. Sampling of microdialysates and venous blood was performed at baseline, at the end of the ertapenem infusion (i.e. 30 min after start of the infusion), in 30 min intervals from 1 to 3 h and in 60 min intervals up to 8 h. Calibration of the microdialysis probes was performed at the end of the study day, using a calibration solution containing ertapenem. Individual probe recoveries were calculated and used to adjust measured free-drug concentrations in the interstitial space fluid of the tissue as previously described. 15 Blood samples were kept on ice for a maximum of 60 min and centrifuged at 3500 rpm for 10 min at 48C to obtain plasma.
Plasma and dialysate samples were immediately snap frozen at 2208C and stored at 2808C until analysis.
HPLC
The concentration of ertapenem in plasma and microdialysate was determined by HPLC. Frozen plasma samples were thawed at room temperature. Briefly, after the addition of 200 mL of methanol to 100 mL of plasma, the samples were centrifuged (13000 g for 5 min) and 80 mL of the supernatant was injected onto the HPLC column. Microdialysate samples (10 mL) were injected onto the column without prior precipitation procedures. The determination of ertapenem was performed using a Dionex UltiMate 3000 system (Dionex Corp., Sunnyvale, CA, USA) with UV detection at 300 nm. Chromatographic separation was carried out at 258C on a Hypersil BDS-C 18 column (5 mm, 250×4.6 mm ID; Thermo Fisher Scientific, Inc., Waltham, MA, USA), preceded by a Hypersil BDS-C 18 pre-column (5 mm, 10×4.6 mm ID). The mobile phase consisted of methanol/5 mM ammonium acetate (10 : 100, v/v) at a flow rate of 1.0 mL/min. Calibration of the chromatogram was accomplished using the external standard method. Linear calibration curves were calculated from the peak areas of ertapenem compared with the external standard by spiking drug-free human plasma and microdialysate with standard solutions of ertapenem to obtain a concentration range of 0.05-10 mg/L (average correlation coefficients .0.99). The limit of quantification for ertapenem in plasma and ultrafiltrate was 0.05 mg/L. The coefficients of accuracy and precision for this compound were ,9%.
Pharmacokinetic analysis
Non-compartmental pharmacokinetic analysis was performed using Kinetica 2000 (version 3.0; Innaphase, Philadelphia, PA, USA). Free plasma concentrations of ertapenem were estimated from total plasma concentrations based on a reported plasma protein binding of 94%. 16 The usual dosing interval of ertapenem is 24 h. In order to determine (i) the areas under the concentration -time curves from 0 to 24 h (AUC 0 -24 s) and (ii) the time above the MIC (T .MIC ) as a percentage of the dosing interval at steady-state, the individual ertapenem concentrations measured on the study day in the plasma and interstitial space fluid of tissues from 0 to 8 h after drug administration were extrapolated to estimate the plasma and tissue concentrations from 8 to 24 h. This was done by using the equation C¼C 0 ×e 2kel×t , where C is the concentration at a defined timepoint, C 0 represents the last concentration measured in vivo (i.e. at 8 h), k el is the elimination rate constant and t is the time between C 0 and the defined timepoint. Descriptive statistics were performed and results presented as means+SD. A two-sided t-test was used to compare the means (software SPSS 16.0.2) of pharmacokinetic parameters between the interstitial space fluid of inflamed subcutaneous tissue (diabetic foot) and of healthy subcutaneous tissue of the ipsilateral thigh.
Results
Ten patients were included in the study. All patients had diabetes mellitus type 2 and a bacterial infection at the lower extremity (infected ulcers, erysipelas and gangrene) requiring antibiotic treatment. One patient was excluded from the analysis due to problems in obtaining adequate samples. At inclusion, diabetes mellitus had been diagnosed for a mean time of 11+10 years (range: newly diagnosed to 27 years). Long-term glucose control, as measured by glycosylated haemoglobin (HbA1c), was poor (8.3%+1.4%). The characteristics of the analysed patients are shown in Table 1 . Most patients had several known comorbidities typically associated with diabetes mellitus, Sauermann et al.
including coronary heart disease (n¼3), peripheral artery occlusive disease (n¼ 4), hypertension (n¼ 5) and obesity with a body mass index ≥30 kg/m 2 (n¼ 6). The mean concentration-versus-time curves of ertapenem at steady-state in plasma and the interstitium of inflamed and of healthy soft tissues of the leg in patients with diabetes mellitus are shown in Figure 1 . The maximum total concentration (C max ) of ertapenem in plasma was 59.4+12.9 mg/L and the apparent volume of distribution at steady-state (V ss ) was 21+4 L. Remarkably, the free C max was significantly higher (P ¼ 0.01) in the interstitium of inflamed tissue (4.5+2.7 mg/L) than of healthy subcutaneous tissue (2.4+1.6 mg/L) of the same leg. AUC 0 -24 s were descriptively but not significantly higher in the interstitium of inflamed tissue than of healthy tissue (23+12 versus 20+10 mg . h/L, respectively). The pharmacokinetic parameters for all studied compartments are shown in Table 2 .
For bacterial pathogens with an MIC of 1 mg/L (for the relevance of this value, please refer to the Discussion section), the mean T .MIC (i.e. the time the free drug concentrations exceed the MIC for a bacterial pathogen) in the interstitium of inflamed tissue was calculated to be 38%+25% (range: 0%-77%) of the 24 h dosing interval. Accordingly, in this study, for bacteria with an ertapenem MIC of 1 mg/L, bacteriostatic (i.e. T .MIC .20%) and maximal bactericidal (i.e. T .MIC .40%) effects would be reached in 8/9 and 4/9 diabetic feet, respectively.
Discussion
Antimicrobial therapy in patients with diabetes mellitus with skin and soft tissue infections is particularly challenging, because wound healing of ulcers is impaired, local circulation is often insufficient due to angiopathy and there is frequent involvement of multidrug-resistant strains. Thus, antibiotic therapy must be cautiously optimized regarding the choice of the antibiotic to cover the causative pathogens, the length of therapy to prevent relapse and the dosing regimen to avoid extensive periods of subinhibitory drug concentrations at the target site resulting in insufficient killing and emergence of antimicrobial resistance. Because knowledge of antibiotic pharmacokinetics at the site of infection is important for optimal dosing, this project was conducted to measure the free concentrations of ertapenem in the interstitium of inflamed and of healthy soft tissues of patients with diabetes mellitus.
It is noteworthy that the C max in plasma (59.4+12.9 mg/L) in diabetics at steady-state (1 g every 24 h) observed in the present study was lower than previously reported from healthy Table 2 . Pharmacokinetic parameters of ertapenem at steady-state (after multiple intravenous infusions of 1 g of ertapenem once daily) in plasma and in the interstitium of inflamed soft tissue of the leg and of healthy soft tissue of the ipsilateral thigh in nine patients with diabetes mellitus (means+SD) 5, 16 However, the current plasma C max of ertapenem in diabetics was closer to the C max (after a single dose of 1 g over 30 min) reported from intensive care unit (ICU) patients with severe sepsis 94.1+79.0 mg/L (geometric mean 52.3 mg/L) 17 and another group of ICU patients reported by Burkhardt et al. 18 (90.5+26.1 mg/L). The pharmacokinetic differences, particularly the higher C max in healthy populations than in the septic or diabetic populations after equal dosing, are not completely clear. As sicker and older populations tend to have a reduced renal function, one might expect rather opposite findings. One reason for the low plasma C max in the current diabetic population seems to be their relatively high mean body weight of 98+22 kg compared with only 64.7+8.6 kg in a previous study in healthy subjects. 5 However, the body weight cannot be the only reason for lower plasma C max in ill subjects because e.g. in the mentioned report from septic patients the mean weight was also only 60.4+12.2 kg. 17 In fact, the V ss of 21+4 L observed presently in diabetics and previously in ICU patients (26.8 L) were markedly higher than those of healthy subjects with V ss of 8.2+1.5 and 15.5+3.4 L. 5, 16, 17 Although a direct comparison of weightcorrected V ss (L/kg) is not feasible due to differences in data presentation between the cited studies, it seems obvious that the higher V ss in ill compared with healthy populations contributes to the observed differences in total plasma drug concentrations.
Among other factors, lower serum albumin concentrations may contribute to higher V ss in patients. 19 Ertapenem has a plasma protein-binding rate of 94%. 16 Lower serum albumin (i.e. 33+3 g/L in the present study compared with 44+3 g/L in a healthy population 5 ) may increase the fraction of unbound drug, 19 thereby facilitating drug diffusion across capillary walls to peripheral compartments in patients. In addition, V ss may be increased by the tendency of sick populations to have either locally or generally increased vascular permeability due to dysfunction of the capillary barriers, as well as by oedemas with higher amounts of extravascular protein, binding drug in the periphery.
The observed free ertapenem concentrations in interstitial tissue fluid were in the magnitude of the calculated free ertapenem concentrations in plasma ( Figure 1) and also of the free interstitial tissue concentrations previously measured in healthy subjects (free C max 3.96+1.63 mg/L, AUC 0 -1 18.6+4.6 mg . h/L), in spite of higher total plasma concentrations in the healthy subjects. 5 Probably, the pathophysiological alterations in patients discussed above (leading to higher V ss ) are also responsible for the relatively high tissue penetration in this study. Thus, the preoccupation previously articulated by Ulldemolins et al.,
19 that higher V ss and lower plasma levels in ill subjects might negatively affect tissue concentrations, seems not to be generally justified.
Interestingly, the free interstitial C max in the inflamed region of the leg (4.5+2.7 mg/L) was significantly higher (P¼ 0.01) than in healthy proximal subcutaneous adipose tissue (2.4+1.6 mg/L). AUC 0 -24 s were descriptively but not significantly higher in the interstitium of inflamed tissue than of healthy tissue (23+12 and 20+10 mg . h/L, respectively). Four of the nine patients had a confirmed diagnosis of peripheral artery occlusive disease of the leg affected by the diabetic foot infection. There was no evident relationship between proven peripheral artery occlusive disease and free interstitial drug tissue concentrations (data not shown). Possibly, inflammationtriggered local alterations explain the higher free ertapenem concentrations in inflamed compared with healthy tissue, outweighing the effects of local macroangiopathy present in several patients. Accordingly, in diabetics with cellulitis, similar free C max values of fosfomycin have been observed in the interstitial space fluid of infected or healthy tissue. 20 According to in vitro data, ertapenem has an MIC 90 for methicillin-susceptible Staphylococcus aureus of 0.25 -0.5 mg/L, for Staphylococcus epidermidis of 0.5-4 mg/L, for oxacillinsusceptible coagulase-negative staphylococci of 0.5 -2 mg/L and for Streptococcus spp. of 0.12-0.5 mg/L. 21 -24 Methicillinresistant S. aureus is considered resistant (MIC 90 .16 mg/L). 21 -24 Escherichia coli and Bacteroides fragilis, as examples of Gram-negative and anaerobic pathogens, were reported to have MIC 90 s of ,0.016-0.12 and 1 mg/L, respectively. 21, 25 ESBLproducing E. coli had an MIC 90 of 0.5 mg/L. 21 Gram-positive bacteria, such as staphylococci and streptococci, are among the most frequent species causing soft tissue infections in diabetics. 26 Based on the present pharmacokinetic data, for bacterial pathogens with an MIC of 1 mg/L the mean T .MIC in the interstitium of infected tissue was calculated to be 38%+25% of the 24 h dosing interval. Bacteriostatic (i.e. T .MIC .20%) 27 and maximal bactericidal (i.e. T .MIC .40%) 27 effects would be reached in 8/9 and 4/9 of the studied diabetic feet, respectively. Assuming an MIC of 0.5 mg/L, bacteriostatic as well as bactericidal effects could be reached in 8/9 patients in the interstitial space fluid of inflamed tissue. This indicates that, in spite of the relatively high tissue penetration of ertapenem (i.e. similar free serum and interstitial tissue concentrations), bactericidal effects might be obtained in more patients if higher daily doses are administered to increase the T .MIC . Higher ertapenem doses may be particularly beneficial for susceptible strains with higher MICs, e.g. of 0.5 -2 mg/L, which can be expected in diabetic patients suffering from chronic skin ulcers and frequently undergoing antibiotic therapies. Because the administration of 2 g of ertapenem over 30 min may lead to side effects such as nausea, reduced administration intervals of 12 h instead of 24 h or continuous infusions may be viable modes to increase daily doses. Assuming a dosing regimen of 1 g of ertapenem twice daily and employing the equation C av(ss) (average concentration at steady-state)¼ AUC total /dosing interval, the mean free C av(ss) could be increased in the interstitial space fluid of inflamed tissue from 0.97+0.52 to 1.94+1.03 mg/L. In this case, bactericidal effects (T .MIC .40%) against strains with an MIC of 1 mg/L could be expected in inflamed tissue of 8/9 of the presently studied subjects (data not shown). Higher ertapenem doses have been discussed also by other researchers to ensure optimal target-attainment rates in different indications, based on pharmacokinetic/pharmacodynamic considerations or Monte Carlo simulations. 17 -19,28,29 In conclusion, this study demonstrated that total plasma concentrations of ertapenem are lower in diabetics at steady-state (1 g once daily) than previously reported for healthy volunteers after a single 1 g dose. In spite of the lower total plasma levels of ertapenem, the unbound interstitial tissue concentrations in diabetics were similar to those known from healthy volunteers. Although 4/9 patients had peripheral artery occlusive disease, the free interstitial ertapenem concentrations were higher in the Sauermann et al.
distal, inflamed tissue of diabetic feet than in proximal healthy adipose tissue, indicating good tissue penetration in diabetic foot infections. In diabetic foot infections caused by moderately susceptible strains, the administration of daily doses of .1 g of ertapenem might be considered to optimize bactericidal effects.
